We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Low-Cost Portable Screening Test to Transform Kidney Disease Detection

By LabMedica International staff writers
Posted on 17 Apr 2025

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. More...

This silent epidemic not only diminishes the quality of life for those affected but also imposes significant financial strain on healthcare systems due to the costs associated with dialysis and organ transplants. However, early diagnosis can significantly alter a patient’s course of treatment, offering better options and potentially halting or slowing the progression of the disease. The challenge lies in the fact that current kidney function tests typically require visits to a laboratory, expensive equipment, skilled personnel, and several days to obtain results. These requirements make routine screenings difficult, particularly for those in rural and Indigenous communities. Now, researchers have created an innovative tool that could revolutionize how kidney disease is diagnosed, especially in underserved areas.

A team of researchers from the University of Manitoba (Winnipeg, Canada) has developed a device known as the uCR-Chip, a low-cost, portable diagnostic tool designed to make kidney function testing faster, more convenient, and widely accessible. The results are available in less than seven minutes, and the test does not require specialized laboratory equipment. Their research, published in Microsystems & Nanoengineering, showcases how this device could play a crucial role in enhancing early detection and improving outcomes for individuals living with chronic kidney disease (CKD). The uCR-Chip addresses the challenges of current testing methods by utilizing a color-based chemical reaction to measure creatinine, a key biomarker of kidney health, from a small urine sample. Since it does not require advanced lab equipment, it can be used directly in health clinics or mobile healthcare settings.

The uCR-Chip has the potential to relieve pressure on healthcare systems by identifying kidney issues at earlier stages, thereby reducing the number of patients who progress to more advanced stages of disease. This could lead to fewer patients requiring costly treatments such as dialysis or transplants, allowing for more effective management with early interventions. In many rural, remote, and Indigenous communities, where access to advanced diagnostic equipment is limited, the uCR-Chip offers a portable, cost-effective alternative that could greatly improve access to vital testing. As healthcare systems worldwide seek affordable solutions to manage chronic diseases, innovations like the uCR-Chip offer not just hope, but tangible solutions that bring life-saving diagnostics to those who need them most.

“Traditional lab test can take days and may delay diagnosis,” said Dr. Francis Lin who led the research team. “Our new test method will lead to faster, more accessible and reliable diagnostic results to prevent irreversible kidney damage.”

Related Links:
University of Manitoba


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.